Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Di Cosimo

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
ESMO Open|July 2, 2023
A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancerC Chiodoni, S Sangaletti, M Lecchi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTOS Di Cosimo, C Campbell, H A Azim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
ESMO Open|July 2, 2023
A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancerC Chiodoni, S Sangaletti, M Lecchi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTOS Di Cosimo, C Campbell, H A Azim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Pageof 4